MONTREAL, Oct. 2 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human proteins, announces that Mr. Joseph Galli, Chairman and Chief Executive Officer, will be presenting at BioContact Quebec 2007. Mr. Galli will be speaking on Wednesday, October 3, 2007 at 16:30 in the Bellevue Room, Chateau Frontenac in Quebec City.
About BioContact Quebec 2007
BioContact Quebec 2007 (http://www.biocontact.qc.ca) is a biopharmaceutical partnership symposium gathering over 1200 participants. More than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cancer, cardiology, drug delivery systems, endocrinology, genomics/proteomics, immunology/infectiology, neurobiology, virology and medical technologies.
Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats.
Haemacure's lead product candidate, Hemaseel(TM)HMN, is a human-derived
fibrin sealant in late-stage clinical development. Haemacure's second
product candidate is human thrombin, a component of its fibrin sealant.
Both candidates have applications in the expanding bio-surgical market.
Follow-on development will focus on surgical hemostats, biomaterial
combinations and drug delivery in select therapeutic areas. Haemacure has
recently discovered additional specialty proteins in its plasma-derived
intermediates and will advance these specialty proteins through
partnerships with other pharmaceutical and biotech
|SOURCE HAEMACURE CORPORATION|
Copyright©2007 PR Newswire.
All rights reserved